|
|
 |
|
Viewing report
|
|
|
|
Biogen Idec: Performance, Products, Pipeline and Potential
Espicom Business Intelligence Ltd, Dec 2010, Pages: 86
Biogen Idec is a global research-based company focused on the development, manufacture and commercialisation of novel therapeutics for human health care. Biogen Idec's headquarters in Cambridge, MA, is strategically close to the renowned research institutions of Harvard, the Massachusetts Institute of Technology, the Whitehead Institute, as well as Novartis' new research HQ and scores of smaller biotech companies. From its headquarters and facilities across the globe, Biogen Idec's marketed products reach patients in more than 90 countries worldwide.
Biogen Idec is gaining a reputation as one of the leading biotechnology innovators, particularly in the fields of cancer and immunology. Compared to the other 'big pharma' players it is still relatively small and its marketing organisation lacks scope and maturity. Traditionally, Biogen Idec has sought out partners to achieve its marketing goals and it has done particularly well from its agreement with Roche/Genentech for Rituxan.
The failure of the company to attract a takeover offer from the major pharmaceutical companies in 2007, means that Biogen Idec will remain an independent company for the time being. Potential bidders may have been put off by the escalating share price, or the risky bet on Biogen Idec and Elan's multiple sclerosis drug, Tysabri, following its linking to a rare brain infection that could reduce the drug's market potential. The successful re-launch and uptake of Tysabri may go some way to allay these fears.
Of its key products, Avonex remains the main growth driver alongside Rituxan, supported by the re-launch of Tysabri for multiple sclerosis (MS).
The group's core asset is its strong pipeline of middle- to late-stage drugs. The pipeline contains some promising line-extensions and biologics for lymphoma, leukaemia and immune disease such as MS, Crohn's disease and rheumatoid arthritis. Of particular note are lumiliximab, which could be the next new medication for chronic lymphocytic leukaemia, galiximab for non-Hodgkin's lymphoma, lixivaptan for heart failure, BG-12 for MS and ocrelizumab, which has the potential to take over from Rituxan in rheumatoid arthritis as well as being used in combination with Rituxan for MS.
These projects may yet make an attractive proposition to any potential suitors, however, should Biogen Idec go it alone, then it will need to enhance its in-house sales and marketing capabilities to successfully bring these to the widest possible market, allowing it to take on more responsibility for its own destiny and to ensure it can achieve organic growth without relying on other potentially competitive companies.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
